Atea Pharmaceuticals just dropped major news: their hepatitis C drug, bemrusasvir, proved just as effective as Epclusa in a tough phase three trial—offering a shorter, simpler cure path for millions, especially those with complex health needs. The company’s global trial is fully enrolled and poised for results in 2027, with regulatory submissions and commercial prep already underway. They’re also pioneering a first-in-human study for chronic hepatitis E—a disease with no approved treatments—and are financially strong with over $219 million to fund operations through 2027. With the hepatitis C market shifting toward “test and treat,” Atea sees a huge opportunity to expand access and help end the epidemic.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
